Top MarketRank™ StocksTop MarketRank™NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis $193.30 +2.42 (+1.27%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$180.45▼$198.2350-Day Range$170.79▼$206.9852-Week Range$125.82▼$283.00Volume1.84 million shsAverage Volume841,799 shsMarket Capitalization$13.54 billionP/E Ratio58.58Dividend YieldN/APrice Target$239.18 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Insulet alerts: Email Address Insulet MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside23.7% Upside$239.18 Price TargetShort InterestHealthy4.24% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.99Based on 22 Articles This WeekInsider TradingSelling Shares$2.64 M Sold Last QuarterProj. Earnings Growth20.90%From $3.11 to $3.76 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.81 out of 5 starsMedical Sector37th out of 936 stocksSurgical & Medical Instruments Industry8th out of 101 stocks 3.4 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageInsulet has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insulet's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.24% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 3.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 3.3 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Insulet this week, compared to 9 articles on an average week.Search Interest9 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,636,286.00 in company stock.Percentage Held by InsidersOnly 0.47% of the stock of Insulet is held by insiders.Read more about Insulet's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 20.90% in the coming year, from $3.11 to $3.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 58.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 58.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.64.Price to Earnings Growth RatioInsulet has a PEG Ratio of 3.50. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 18.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insulet's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Insulet Stock (NASDAQ:PODD)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PODD Stock News HeadlinesJuly 26 at 8:01 AM | benzinga.comWhy Is Omnipod Insulin Device Maker Insulet Stock Jumping Today?July 25 at 2:00 AM | americanbankingnews.comInsulet Co. (NASDAQ:PODD) Receives $239.18 Average PT from AnalystsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 23 at 5:14 PM | markets.businessinsider.comInsulet’s Growth Prospects Bolstered by AID Technology and Strategic Market ExpansionJuly 23 at 12:12 PM | markets.businessinsider.comA Closer Look at 7 Analyst Recommendations For InsuletJuly 23 at 8:48 AM | americanbankingnews.comCanaccord Genuity Group Reaffirms "Buy" Rating for Insulet (NASDAQ:PODD)July 20, 2024 | americanbankingnews.comInsulet Co. to Post FY2024 Earnings of $3.38 Per Share, Leerink Partnrs Forecasts (NASDAQ:PODD)July 19, 2024 | americanbankingnews.comQ4 2024 Earnings Forecast for Insulet Co. Issued By Leerink Partnrs (NASDAQ:PODD)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 30, 2024 | seekingalpha.comInsulet tops S&P 500 growth chart for Q2 as it gains market share in the diabetes spaceJune 21, 2024 | businesswire.comInsulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 DiabetesJune 20, 2024 | businesswire.comInsulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the NetherlandsJune 19, 2024 | investorplace.comThe 3 Best Diabetes Stocks to Buy in June 2024June 11, 2024 | gurufocus.comInsider Sale: Director Timothy Scannell Sells 7,000 Shares of Insulet Corp (PODD)June 11, 2024 | seekingalpha.comInsulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023May 28, 2024 | businesswire.comInsulet to Present at the Jefferies Global Healthcare ConferenceMay 22, 2024 | finance.yahoo.comInsulet Corporation (PODD)May 19, 2024 | investorplace.comFollow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit GainsSee More Headlines Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$239.18 High Stock Price Target$330.00 Low Stock Price Target$184.00 Potential Upside/Downside+27.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$3.30 Trailing P/E Ratio56.95 Forward P/E Ratio60.43 P/E Growth3.5Net Income$206.30 million Net Margins13.14% Pretax Margin13.75% Return on Equity34.06% Return on Assets9.08% Debt Debt-to-Equity Ratio1.72 Current Ratio3.74 Quick Ratio2.75 Sales & Book Value Annual Sales$1.78 billion Price / Sales7.39 Cash Flow$3.67 per share Price / Cash Flow51.22 Book Value$10.49 per share Price / Book17.92Miscellaneous Outstanding Shares70,040,000Free Float69,711,000Market Cap$13.16 billion OptionableOptionable Beta1.16 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. James R. Hollingshead Ph.D. (Age 61)President, CEO & Director Comp: $2.88MMs. Lauren Budden (Age 49)Group VP, Chief Accounting Officer & Controller Comp: $794.05kMr. Mark Field (Age 53)Senior VP & CTO Comp: $954.14kMr. John Wodick Kapples (Age 64)Senior VP & General Counsel Comp: $1.02MMs. Shacey Petrovic (Age 51)Director & Advisor Comp: $28.57kMr. Eric Benjamin (Age 41)Executive VP, Chief Product & Customer Experience Officer Comp: $1.14MMs. Ana Maria Chadwick (Age 52)Executive VP, CFO & Treasurer Mr. Prem Singh (Age 47)Senior Vice President of Global Operations Ms. Deborah R. Gordon CPA (Age 53)Vice President of Investor Relations Ms. Laetitia Cousin (Age 48)Senior VP of Regulatory Affairs, Quality Assurance & Compliance More ExecutivesKey CompetitorsAbiomedNASDAQ:ABMDNovoCureNASDAQ:NVCREdwards LifesciencesNYSE:EWDexComNASDAQ:DXCMIDEXX LaboratoriesNASDAQ:IDXXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 3,433 shares on 7/26/2024Ownership: 0.675%State of Michigan Retirement SystemBought 100 shares on 7/26/2024Ownership: 0.027%EFG Asset Management North America Corp.Sold 758 shares on 7/26/2024Ownership: 0.015%Dearborn Partners LLCBought 1,000 shares on 7/26/2024Ownership: 0.001%Mn Services Vermogensbeheer B.V.Sold 700 shares on 7/25/2024Ownership: 0.039%View All Insider TransactionsView All Institutional Transactions PODD Stock Analysis - Frequently Asked Questions How have PODD shares performed this year? Insulet's stock was trading at $216.98 at the start of the year. Since then, PODD shares have decreased by 10.9% and is now trading at $193.30. View the best growth stocks for 2024 here. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) issued its earnings results on Thursday, May, 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.34. The company's revenue was up 23.3% on a year-over-year basis. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Insulet's major shareholders? Insulet's top institutional shareholders include Baillie Gifford & Co. (2.69%), Bank of New York Mellon Corp (0.67%), AMI Asset Management Corp (0.41%) and Assenagon Asset Management S.A. (0.26%). Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, Wayde D Mcmillan, Bret Christensen, Mark N Field, Michael P Spears, Dan Manea, Prem Singh, Shacey Petrovic and Luciana Borio. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ) and Walt Disney (DIS). This page (NASDAQ:PODD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
